Niida M, Yoshida T, Kohmoto A, Ogawa M, Hashimoto H, Deguchi K
Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
Jpn J Antibiot. 1994 Jan;47(1):1-10.
We studied the combined effect of fosfomycin (FOM) with sulbactam/cefoperazone (SBT/CPZ) on clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA, 246 strains) and Pseudomonas aeruginosa (190 strains) in vitro. In ratio of mixed serum concentration of antibiotics at three hours after intravenous administration, the combination of FOM with SBT/CPZ and alone of arbekacin showed over 90% in cumulative percentage of MIC against MRSA and P. aeruginosa. The effect of the combination of FOM and SBT/CPZ was observed in MRSA strains of > 16 micrograms/ml of SBT/CPZ MIC and > 256 micrograms/ml FOM MIC. As well as in P. aeruginosa strains, the effect of the combination of FOM and SBT/CPZ was observed in strains of > 16 micrograms/ml of SBT/CPZ MIC and < 256 micrograms/ml FOM MIC, but it was not remarkable in strains of > 256 micrograms/ml FOM MIC. These results suggests that the combination treatment of FOM and SBT/CPZ may be effective for mixed infection of MRSA and P. aeruginosa.
我们在体外研究了磷霉素（FOM）与舒巴坦/头孢哌酮（SBT/CPZ）联合使用对耐甲氧西林金黄色葡萄球菌（MRSA，246株）和铜绿假单胞菌（190株）临床分离株的作用。以静脉给药三小时后抗生素混合血清浓度的比例计算，FOM与SBT/CPZ联合使用以及单独使用阿贝卡星对MRSA和铜绿假单胞菌的累积MIC百分比均超过90%。在SBT/CPZ MIC＞16微克/毫升且FOM MIC＞256微克/毫升的MRSA菌株中观察到FOM与SBT/CPZ联合使用的效果。在铜绿假单胞菌菌株中，在SBT/CPZ MIC＞16微克/毫升且FOM MIC＜256微克/毫升的菌株中观察到FOM与SBT/CPZ联合使用的效果，但在FOM MIC＞256微克/毫升的菌株中效果不显著。这些结果表明，FOM与SBT/CPZ联合治疗可能对MRSA和铜绿假单胞菌混合感染有效。
